Multiple system atrophy, parkinsonian type (MSA-p) is a form of multiple system atrophy (MSA) with predominant parkinsonian features (bradykinesia, rigidity, irregular jerky postural tremor, and postu...
Comprehensive, easy-to-understand information about this condition
How we create this content →The limited documentation surrounding multiple system atrophy, parkinsonian type (MSA-p) can be frustrating. This condition affects a small population, making large-scale systematic studies challenging. Additionally, the clinical features may overlap with other neurodegenerative disorders, complicating the characterization of MSA-p. As research continues, there is hope for a clearer understanding of this condition.
To navigate your care for multiple system atrophy, parkinsonian type, it is advisable to seek a neurologist with expertise in movement disorders, particularly those familiar with atypical parkinsonian syndromes. While there are currently no specific patient organizations identified for MSA-p, resources like the National Organization for Rare Disorders (NORD) at rarediseases.org may provide valuable information and support. Additionally, inquire about participation in clinical trials, as these can offer access to cutting-edge treatments and contribute to the understanding of MSA-p.
Currently, there are two orphan drugs designated for MSA-p in development. These include monoclonal antibodies against alpha-synuclein and other compounds aimed at addressing the underlying mechanisms of the disease. There are also seven active clinical trials investigating various aspects of MSA-p. For more information on these trials, you can visit the ClinicalTrials.gov search page: https://clinicaltrials.gov/search?cond=multiple%20system%20atrophy%2C%20parkinsonian%20type.
Actionable guidance for navigating care for multiple system atrophy, parkinsonian type
To navigate your care for multiple system atrophy, parkinsonian type, it is advisable to seek a neurologist with expertise in movement disorders, particularly those familiar with atypical parkinsonian syndromes. While there are currently no specific patient organizations identified for MSA-p, resources like the National Organization for Rare Disorders (NORD) at rarediseases.org may provide valuable information and support. Additionally, inquire about participation in clinical trials, as these can offer access to cutting-edge treatments and contribute to the understanding of MSA-p.
Consider asking your healthcare providers these condition-specific questions
Helpful links for rare disease information and support
The limited documentation surrounding multiple system atrophy, parkinsonian type (MSA-p) can be frustrating. This condition affects a small population, making large-scale systematic studies challenging. Additionally, the clinical features may overlap with other neurodegenerative disorders, complicating the characterization of MSA-p. As research continues, there is hope for a clearer understanding of this condition.
To navigate your care for multiple system atrophy, parkinsonian type, it is advisable to seek a neurologist with expertise in movement disorders, particularly those familiar with atypical parkinsonian syndromes. While there are currently no specific patient organizations identified for MSA-p, resources like the National Organization for Rare Disorders (NORD) at rarediseases.org may provide valuable information and support. Additionally, inquire about participation in clinical trials, as these can offer access to cutting-edge treatments and contribute to the understanding of MSA-p.
Currently, there are two orphan drugs designated for MSA-p in development. These include monoclonal antibodies against alpha-synuclein and other compounds aimed at addressing the underlying mechanisms of the disease. There are also seven active clinical trials investigating various aspects of MSA-p. For more information on these trials, you can visit the ClinicalTrials.gov search page: https://clinicaltrials.gov/search?cond=multiple%20system%20atrophy%2C%20parkinsonian%20type.
Actionable guidance for navigating care for multiple system atrophy, parkinsonian type
To navigate your care for multiple system atrophy, parkinsonian type, it is advisable to seek a neurologist with expertise in movement disorders, particularly those familiar with atypical parkinsonian syndromes. While there are currently no specific patient organizations identified for MSA-p, resources like the National Organization for Rare Disorders (NORD) at rarediseases.org may provide valuable information and support. Additionally, inquire about participation in clinical trials, as these can offer access to cutting-edge treatments and contribute to the understanding of MSA-p.
Consider asking your healthcare providers these condition-specific questions
Helpful links for rare disease information and support
The limited documentation surrounding multiple system atrophy, parkinsonian type (MSA-p) can be frustrating. This condition affects a small population, making large-scale systematic studies challenging. Additionally, the clinical features may overlap with other neurodegenerative disorders, complicating the characterization of MSA-p. As research continues, there is hope for a clearer understanding of this condition.
To navigate your care for multiple system atrophy, parkinsonian type, it is advisable to seek a neurologist with expertise in movement disorders, particularly those familiar with atypical parkinsonian syndromes. While there are currently no specific patient organizations identified for MSA-p, resources like the National Organization for Rare Disorders (NORD) at rarediseases.org may provide valuable information and support. Additionally, inquire about participation in clinical trials, as these can offer access to cutting-edge treatments and contribute to the understanding of MSA-p.
Currently, there are two orphan drugs designated for MSA-p in development. These include monoclonal antibodies against alpha-synuclein and other compounds aimed at addressing the underlying mechanisms of the disease. There are also seven active clinical trials investigating various aspects of MSA-p. For more information on these trials, you can visit the ClinicalTrials.gov search page: https://clinicaltrials.gov/search?cond=multiple%20system%20atrophy%2C%20parkinsonian%20type.
Actionable guidance for navigating care for multiple system atrophy, parkinsonian type
To navigate your care for multiple system atrophy, parkinsonian type, it is advisable to seek a neurologist with expertise in movement disorders, particularly those familiar with atypical parkinsonian syndromes. While there are currently no specific patient organizations identified for MSA-p, resources like the National Organization for Rare Disorders (NORD) at rarediseases.org may provide valuable information and support. Additionally, inquire about participation in clinical trials, as these can offer access to cutting-edge treatments and contribute to the understanding of MSA-p.
Consider asking your healthcare providers these condition-specific questions
Helpful links for rare disease information and support
Clinical profile data for this condition is not yet available. Phenotype information may still be loading below.
Research studies investigating treatments and therapies for this condition.
Active Trials
Total Trials
Data from ClinicalTrials.gov Jan 30, 2026
Consider asking your healthcare providers these condition-specific questions
European rare disease database
Genetic and Rare Diseases Info Center
AI-Generated Content: This summary was generated using AI. Content has been fact-checked. Always consult with qualified healthcare providers for medical guidance.
Kisho delivers this disease record via API, including phenotypes (HPO), genes, orphan drug designations, screening status, and PAG mapping, with version history and governance.
Organizations with orphan designations or approved therapies for this disease